Thienopyrrole acetic acids as antagonists of the CRTH2 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 6, 2011, Pages 1861-1864

  Bonafoux, Dominique ^a   Abibi, Ayome ^a   Bettencourt, Brian ^a   Burchat, Andrew ^a   Ericsson, Anna ^a   Harris, Christopher M ^a   Kebede, Tegest ^a   Morytko, Michael ^a   McPherson, Michael ^a   Wallace, Grier ^a   Wu, Xiaoyun ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Bioavailability; CRTH2 receptor; DP1 receptor; PK; Thienopyrroles

Indexed keywords

CHEMOATTRACTANT RECEPTOR HOMOLOGOUS EXPRESSED ON TH2 CELLS; DOFETILIDE; G PROTEIN COUPLED RECEPTOR; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; THIENOPYRROLE ACETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RECEPTOR BINDING; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ACETIC ACIDS; ANIMALS; BIOLOGICAL AVAILABILITY; MICE; MICROSOMES, LIVER; PYRROLES; RATS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

MUS;

EID: 79952361716     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.008     Document Type: Article

References (27)

1. R.A. Lewis, N.A. Soter, P.T. Diamond, K.F. Austen, J.A. Oates, and L.J. Roberts J. Immunol. 129 1982 1627
2. S.P. Peters, R.P. Scheimer, and A. Kagey-Sobotka Trans. Assoc. Am. Physician 95 1982 221
3. J.J. Murray, A.B. Tonnel, and A.R. Brash N. Engl. J. Med. 315 1986 800
4. R.M. Naclerio, H.L. Meier, A. Kagey-Sobotka, N.F. Adkinson Jr., D.A. Meyers, and P.S. Norman Am. Rev. Respir. Dis. 128 1983 597
5. E.N. Charlesworth, A. Kagey-Sobotka, R.P. Schleimer, P.S. Norman, and L.M. Lichtenstein J. Immunol. 146 1991 671
6. H. Hirai J. Exp. Med. 193 2001 255
7. J.F. Royer, P. Schratl, R. Jupp, J. Barker, C. Weyman-Jones, R. Beri, C. Sargent, J.A. Schmidt, D. Lang-Loidolt, and A. Heinemann Eur. J. Clin. Invest. 38 2008 663
8. L. Xue, A. Barrow, and R. Pettipher J. Immunol. 182 2009 7580
9. T. Satoh, R. Moroi, K. Aritake, Y. Kania, and K. Sumi J. Immunol. 177 2006 2621
10. L. Uller, J.M. Mathiesen, L. Alenmyr, M. Korsgren, T. Ulven, and T. Hogberg Respir. Res. 8 2007 16
11. B.A. Stearns, C. Baccei, G. Bain, A. Broadhead, R.C. Clark, H. Coate, J.F. Evans, P. Fagan, J.H. Hutchinson, C. King, C. Lee, D.S. Lorrain, P. Prasit, P. Prodanovich, A. Santini, J.M. Scott, N.S. Stock, and Y.P. Truong Bioorg. Med. Chem. Lett. 19 2009 4647
12. Oxagen Ltd Press release, Dec. 9th, 2009.
13. N. Sawyer Br. J. Pharmacol. 137 2002 1163
14. H. Hirai J. Immunol. 168 2002 981
15. H. Sugimoto, M. Shichijo, T. Iino, Y. Manabe, A. Watanabe, M. Shimazaki, F. Gantner, and K.B. Bacon J. Pharmacol. Exp. Ther. 305 2003 347
16. T. Ulven, and E. Kostenis Curr. Top. Med. Chem. 6 2006 1247
17. R. Pettipher, T.T. Hansel, and R. Armer Nat. Rev. Drug Disc. 6 2007 313
18. R.E. Armer, M.R. Ashton, E.A. Boyd, C.J. Brennan, F.A. Brookfield, L. Gazi, S.L. Gyles, P.A. Hay, M.G. Hunter, D. Middlemiss, M. Whittaker, L. Xue, and R. Pettipher J. Med. Chem. 48 2005 6174
19. T.N. Birkinshaw, S.J. Teague, C. Beech, R.V. Bonnert, S. Hill, A. Patel, S. Reakes, H. Sanganee, I.G. Dougall, T.T. Phillips, S. Salter, J. Schimdt, E.C. Arrowsmith, J.J. Carrillo, F. Bell, S.W. Paine, and R. Weaver Bioorg. Med. Chem. Lett. 16 2006 4287
20. D.A. Sandham, C. Adcock, B. Kamlesh, L. Barker, Z. Brown, G. Dubois, D. Budd, B. Cox, R.A. Fairhurst, M. Furegati, C. Leblanc, J. Manini, R. Profit, J. Reilly, R. Stringer, A. Schmidt, K.L. Turner, S.J. Watson, J. Willis, G. Williams, and C. Wilson Bioorg. Med. Chem. Lett. 19 2009 4794
21. (a) WO 2006/021418; (b) WO 2006/034418.
22. S. Crosignani, P. Page, M. Missotten, V. Colovray, C. Cleva, J.-F. Arrighi, J. Atherall, J. Macritchie, T. Martin, Y. Humbert, M. Gaudet, D. Pupowicz, M. Maio, P.-A. Pittet, L. Golzio, C. Giachetti, C. Rocha, G. Bernardinelli, Y. Filinchuk, A. Scheer, M.K. Schwarz, and A. Chollet J. Med. Chem. 51 2008 2227
23. WO 2006/136859; WO 2007/031747.
24. Radioligand binding assays were performed with membranes prepared from HEK293 cells expressing human CRTH2 or DP-1. All compounds were dissolved in DMSO and assays run at a final DMSO concentration of 1% (v/v). [3H]-labeled PGD2 was purchased from PerkinElmer and used at a final concentration of 1 nM for CRTH2 or 2 nM for DP-1.
25. D. Wensbo, U. Annby, and S. Gronowitz Tetrahedron 37 1995 10323
26. R.G. Shea, J.N. Fitzner, J.E. Fankhauser, A. Spaltenstein, P.A. Carpino, R.M. Peevey, D.V. Pratt, B.J. Tenge, and P.B. Hopkins J. Org. Chem. 51 1986 5252
27. Calcium flux assays were performed in CHO cells expressing human CRTH2 and the Gα16 coupling protein using a FLIPR instrument (Molecular Devices). All compounds were dissolved in DMSO and assays run at a final DMSO concentration of 1% (v/v). PGD2 was purchased from Cayman Chemicals and used at a final assay concentration of 1 μM.